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A B S T R A C T
A 65-year-old male on hemodialysis three times a week due to end-stage renal failure underwent cardiac
surgery one year previously, and complained of breathlessness on exertion after surgery.
Echocardiograms evidenced a signiﬁcant obstruction in the left ventricular outﬂow with intraventricular
pressure gradient of 62 mmHg, and the patient was started on beta-blocker. After a maximal dose of
carvedilol was given, a class 1A antiarrhythmic drug of Na channel blocker, procainamide, was added
because of insufﬁcient relief of symptoms. Electrocardiogram (ECG) showed prolonged QT intervals
(523 ms) on a regular visit one month after the administration of procainamide, and the dose of
procainamide was decreased. On the next day, he was brought to our hospital due to cardiac pulmonary
arrest. Initial rhythm was ventricular ﬁbrillation and the corrected QT intervals (QTc) were prolonged
(531 ms). Blood examination revealed that N-acetyl procainamide (NAPA), metabolite of procainamide,
was signiﬁcantly higher than the recommended threshold. NAPA was identiﬁed as the cause of
prolonged QTc and procainamide was stopped. NAPA decreased under the recommended threshold on
the seventh day and the QT intervals were normalized. This case report outlines the ﬁrst case of long QT
syndrome caused by NAPA in a hemodialysis patient.
<Learning objective: Administration of procainamide could be dangerous even in patients undergoing
hemodialysis whose serum procainamide level is within normal limits. We should pay careful attention
to it and must not forget to measure the concentrations of procainamide and NAPA. The measurement of
QT intervals could help to avoid a fatal side effect.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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We sometimes encounter patients with hypertrophic obstruc-
tive cardiomyopathy (HOCM) who need administration of Na
channel blockers in addition to beta-blockers. They may be
administered safely in many patients, but some Na channel
blockers and their metabolites have K channel blockade proﬁles,
which could provoke QT interval prolongation in a small number of
patients. We encountered a patient on hemodialysis in whom the
QT intervals were prolonged by procainamide metabolite, N-acetyl
procainamide (NAPA). While it is well known that NAPA is more
likely to accumulate in the body than procainamide, this is the ﬁrst* Corresponding author at: Cardiovascular Division, Department of Internal
Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya 663-8501,
Japan. Tel.: +81 798 45 6553; fax: +81 798 45 6551.
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1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsreport of long QT syndrome caused by this drug in a hemodialysis
patient. We are presenting this case with literature reviews.
Case report
A 65-year-old man, who was on dialysis three times a weeks
due to end-stage renal failure, received surgical repair of
abdominal aortic aneurysm and mitral valve plasty one year prior
to this hospitalization. He had been taking 75 mg of cinacalcet,
15 mg of lansoprazole, and 100 mg of aspirin once a day.
The patient had increasingly complained of breathlessness
on exertion after surgery. While there was lack of evidence of
hypertrophic cardiomyopathy before surgery, echocardiography
showed intraventricular septum thickness of 18 mm and posterior
wall thickness of 10 mm, indicating asymmetrical septal hyper-
trophy. There was an intracavitary pressure gradient of 62 mmHg,
and left ventricular ejection fraction was 71%. Administration of
beta-blocker with carvedilol was started. Its dose was titrated up reserved.
Fig. 1.
Electrocardiogram comparing baseline (before administration of procainamide), the ﬁrst day of hospitalization (Day 1), and the seventh day of hospitalization
(Day 7). Before administration, corrected QT intervals (QTc) were within normal limits (453 ms); however, QTc were prolonged at Day 1 (531 ms). After
consecutive renal replacement therapy, QTc were resolved within normal limits at Day 7 (451 ms).
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daily). He continued to experience general fatigue and breathless-
ness on exertion; therefore, class 1A Na channel blocker
(procainamide 750 mg/day) was added. After that, shortness of
breath was almost resolved and intraventricular pressure gradient
decreased from 62 mmHg to 45 mmHg. Electrocardiogram (ECG)
at a regular clinical visit one month later showed QT prolongation
and QTc intervals were 523 ms even though they were within
normal limits before the administration of procainamide. The
dosage of procainamide was decreased from 750 to 500 mg daily.
On the next day, his wife found him unconscious in his bedroom
and emergency medical service (EMS) was called. When EMS
arrived on the scene, all his vital signs were absent, indicating
cardiac pulmonary arrest (CPA). Automatic external deﬁbrillator
was attached and the ﬁrst analysis showed shockable rhythm.
After DC shock, 14 min of cardiac pulmonary resuscitation
resuscitated him. Later, the rhythm was revealed as ventricular
ﬁbrillation. When he was brought to our hospital, his blood
pressure was 172/65 mmHg, heart rate was 50 bpm, ECG monitor
displayed regular sinus rhythms, body temperature was 36.5 8C,
and level of consciousness was semi coma (Japan Coma Scale: III-
100 and Glasgow Coma Scale: E2V4M6). An arteriovenous shunt,
which was located in his left arm, sounded good. No additional
cardiac sounds were detected but wheezing was prominent in both
lateral areas of the lungs. Venous blood gas analysis revealed mild
respiratory acidosis, which was considered as the main reason for
persistent conscious disturbance. Blood chemistry test revealed
slightly elevated serum K level of 5.7 mEq/L, which was unlikely
regarded as the cause of CPA. ECG showed normal axis. PR intervals
(188 ms) and QRS durations (110 ms) were within normal limits,
but QTc intervals were prolonged to 531 ms (Fig. 1). Echocardio-
grams showed no remarkable changes compared to the images
recorded one month before. Coronary angiography showed normal
vessels.Table 1 Serum concentrations of procainamide, N-acetyl procainamide (NAPA).
Day 1 Day 7
Procainamide (mg/mL)
Criteria: 4–10 mg/mL
2.6 <0.1
NAPA (mg/mL)
Criteria: 10–20 mg/mL
27.7 8.1We investigated blood concentrations of procainamide and
NAPA. The concentration of procainamide was 2.6 mg/mL below
the recommended threshold; however, that of NAPA was 27.7 mg/
mL beyond the recommended threshold (Table 1). Procainamide
administration was stopped, and consecutive renal replacement
therapy was performed for 7 days. Hypothermotherapy was
introduced and his consciousness was restored. The concentra-
tions of procainamide and NAPA on the seventh day were below
the recommended threshold. The QTc intervals were normalized in
ECG (451 ms, Fig. 1). He was discharged from the hospital without
neurological sequelae on the 43rd day.
Discussion
Patients with HOCM often complain of dyspnea on exertion
related to exacerbation of intraventricular pressure gradient. Beta-
blockers are usually administered as ﬁrst-line drugs. However,
further medication is required because of insufﬁcient beneﬁts of
beta-blockers alone in some patients. Class 1A Na channel blocker
is used as an additional therapy in these patients.
Antiarrhythmic drugs have proarrhythmic proﬁle. The most
serious consequence is prolonged QTc intervals due to prolonged
action potential durations, which are mainly conﬁgured between
phase 0 and 3 of myocardial potential [1,2]. The phase 3 is mainly
regulated by the repolarizing currents such as IKs or IKr.
Procainamide and NAPA inhibit IKr as class 3 antiarrhythmic
drugs [3] and work more strongly as heart rate decreases, which is
known as reverse frequency dependence [1]. We had a concern
that the direct inﬂuence by a class 1A drug caused micro-reentry
on pathogenic myocardial muscle of HOCM. One observational
study, however, revealed that there were no signiﬁcant differences
in cardiac events between class 1A drug arm and the other arm
[4]. In our clinical practice, QT prolongation was obvious and the
direct inﬂuence was not taken into account.
In our patient, procainamide at normal level was not a culprit
drug for QT prolongation, but NAPA at toxic concentration was. It is
estimated that 40% and 60% of procainamide are renally excreted
and metabolized in the liver into NAPA by N-acetyltransferase II,
respectively. In patients without renal or hepatic malfunction,
procainamide can be given safely within permissible dosage,
except for potential Brugada’s syndrome patients [5]. The dialysis
rate of procainamide and NAPA was 30% and it is not sometimes
controlled strictly in hemodialysis patients compared to renally
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accumulate in the body more than procainamide does because of
different pharmacokinetics [6]. For one thing, a rapid phenotype of
N-acetyltransferase II, which exists in the majority of Japanese
people, might contribute to elevation of NAPA/procainamide ratio.
As a result, the concentration of NAPA, regardless of equivalent
dialysis rate, remained at higher levels whereas the concentration
of procainamide did not. A former report revealed the importance
of measuring serum levels of both procainamide and NAPA even
in hemodialysis patients [7]. A clinical trial demonstrated that
NAPA could cause long QT syndrome [8] and there were also prior
case reports of procainamide/NAPA-related long QT syndrome in
renally impaired patients without hemodialysis [9,10]. On the
other hand, the excretion of procainamide and NAPA is facilitated
in patients undergoing hemodialysis. Therefore, QT prolongation
should be more unlikely in patients undergoing hemodialysis than
in patients without hemodialysis. However, we believe that this is
the ﬁrst report of a hemodialysis patient with long QT syndrome
induced by procainamide and NAPA. Any lethal arrhythmias had
not been reported in hemodialysis patients previously even if the
concentration of NAPA was at toxic levels [9]. The presence of
hypertrophic cardiomyopathy may have affected QTc intervals and
triggered abnormal electrical activities in our patient.
Our patient had taken 10 mg of carvedilol twice daily and it
decreased heart rate. In his situation, IKr was strongly inhibited
with reverse frequency dependence, and eventually it was related
to drug-induced long QT syndrome. It was difﬁcult to avoid heart
rate drop because of the necessity of beta blockade in our patient.
We should have measured procainamide and NAPA concentra-
tions and QTc intervals one week after the administration of
procainamide.
After removal of procainamide, his dry weight was not set
strictly at the ideal level because mild dyspnea presented due to
intraventricular obstruction. In the future, if heart failure worsens
or if he suffers from breathlessness, surgical septal-myectomy or
percutaneous transluminal septal myocardial ablation should be
considered.
Thus, we observed secondary long QT syndrome caused by
NAPA in a hemodialysis patient. Although procainamide is notabsolutely contraindicated and is able to be administered even in
patients with renal dysfunction, it can be a harmful prescription.
We should remember that antiarrhythmic drugs affect multi
channels in vivo and that there is a probability that side effects can
be induced even if dialyzable drugs are used in hemodialysis
patients. The frequent evaluations of QT intervals with measure-
ments of serum procainamide and NAPA levels can help to avoid
a fatal side effect.
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